arrow
B

Brian J. Mog

Howard Hughes Medical Institute
H指数:13
被引数:1,634

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Publisher Correction: Mutant KRAS vaccine with dual checkpoint blockade in resected pancreatic cancer: a phase I trial

Publisher Correction: 突变KRAS疫苗联合双重免疫检查点阻断在切除的胰腺癌中的I期临床试验

2026-04-150
OAAI
Mutant KRAS vaccine with dual checkpoint blockade in resected pancreatic cancer: a phase I trial

携带双检查点阻断的突变KRAS疫苗在切除的胰腺癌中的应用:一项I期临床试验

2026-02-100
OAAI
Bispecific antibodies and CAR T cells targeting a TP53 mutation-associated neoantigen show discordant affinity requirements

双特异性抗体和靶向TP53突变相关新抗原的CAR T细胞显示出不同的亲和力需求

2026-01-160
OA
TRBC2-targeting antibody–drug conjugates for the treatment of T cell cancers

用于治疗T细胞癌症的TRBC2-targeting抗体-药物结合物

2025-12-220
PRE
Preclinical studies show that Co-STARs combine the advantages of chimeric antigen and T cell receptors for the treatment of tumors with low antigen densities
2024-07-101
PRE
TRBC1-targeting antibody–drug conjugates for the treatment of T cell cancers

用于治疗T细胞癌症的TRBC1-targeting抗体-药物结合物

Nature
IF48.5
2024-03-270
PRE
Hydrophobic interactions dominate the recognition of a KRAS G12V neoantigen

疏水相互作用主导了KRAS G12V新抗原的识别

2023-08-218
OAAI
Hybrid TCR-CAR design surpasses conventional CARs and patient-derived TCRs in targeting an ultra-low-density neoantigen
2023-04-140
PRE
Structural engineering of chimeric antigen receptors targeting HLA-restricted neoantigens

靶向HLA限制性新抗原的嵌合抗原受体的结构工程

2021-09-0625
OAAI
Transcriptional programs of neoantigen-specific TIL in anti-PD-1-treated lung cancers

anti-PD-1-treated肺癌中新抗原特异性TIL的转录程序

Nature
IF48.5
2021-07-210
OAAI
Targeting public neoantigens for cancer immunotherapy
2021-05-1793
OAAI
Targeting loss of heterozygosity for cancer-specific immunotherapy

靶向杂合性缺失的癌症特异性免疫治疗

2021-03-1751
OAAI
TCR β chain-directed bispecific antibodies for the treatment of T cell cancers
2021-03-1040
OA
Bispecific antibodies targeting mutant RAS neoantigens
2021-03-04122
OAAI